Last reviewed: July 3, 2026
Last updated: July 3, 2026
Written by:
Jay Hastings,
CEO of PlexusDx
Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.
Medically reviewed by:
Jayden Lee, PharmD, EMBA
Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.
This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.
Semaglutide has transformed weight loss outcomes for millions, with clinical trials showing up to 16% body weight reduction over 68 weeks. However, if you're planning pregnancy, you'll want to understand how GLP-1 receptor agonists interact with conception, fetal development, and maternal health. This guide breaks down what research shows and how to coordinate your treatment plan with family planning goals.
How Semaglutide Affects Fertility and Conception
GLP-1 medications like semaglutide don't directly impair fertility in either men or women based on current evidence. The drug works by slowing gastric emptying and signaling satiety in your brain—mechanisms that don't target reproductive hormones or ovulation. However, rapid weight loss itself can temporarily affect menstrual regularity and ovulation, particularly if you lose more than 10% of body weight within a few months. This metabolic shift is reversible and typically normalizes once weight stabilizes.
Animal studies have not shown semaglutide to reduce fertility rates or sperm production at therapeutic doses. Human fertility data remain limited because most clinical trials excluded people trying to conceive. If you're actively attempting pregnancy, discussing your timeline with your doctor before starting semaglutide allows for better planning—whether that means starting treatment after conception attempts, pausing mid-therapy, or switching to alternative weight management strategies.
Semaglutide Safety During Pregnancy: What the Evidence Shows
The FDA classifies semaglutide as Category C for pregnancy, meaning animal studies showed some risk but human data are insufficient. This classification has led most medical societies, including the American College of Obstetricians and Gynecologists (ACOG), to recommend discontinuing GLP-1 medications at least two weeks before attempting conception or as soon as pregnancy is confirmed. No large-scale human trials have examined outcomes in pregnancies exposed to semaglutide, making a cautious approach medically appropriate.
Limited case reports and small observational studies have not identified a clear pattern of birth defects associated with early semaglutide exposure, but the sample sizes are too small to rule out rare complications. Pregnancy itself increases the risk of gestational diabetes and preeclampsia in women with obesity, creating a complex clinical calculus: untreated obesity carries known risks, while continuing semaglutide through pregnancy lacks adequate safety data. Your obstetric team should weigh your individual health profile when making this decision.
Planning Your GLP-1 Treatment Timeline Around Pregnancy
If you know you want to pursue pregnancy within the next 6–12 months, starting semaglutide now can still be beneficial if you coordinate the timing carefully. Many women achieve significant weight loss and improved metabolic health within 6–8 months of treatment, then pause the medication before attempting conception. This approach allows you to reach a healthier weight baseline and reduce pregnancy-related metabolic complications without exposing a developing fetus to the drug.
PlexusDx's compounded semaglutide injection (starting at $149/month) and oral formulations offer flexible dosing schedules, so you can taper off gradually as you approach your conception window rather than stopping abruptly. Working with your prescriber and OB/GYN in parallel ensures both teams understand your plan. Some patients choose to resume semaglutide after pregnancy and breastfeeding if weight loss remains a health priority.
Metabolic Health and Pregnancy Outcomes in Women with Obesity
Weight loss achieved before pregnancy—independent of the medication used—significantly reduces the risk of gestational diabetes, preeclampsia, and cesarean delivery. Studies show that women who achieve even a 5–10% weight loss improvement before conception experience better obstetric outcomes. If semaglutide helps you reach that target and you discontinue it before pregnancy, you preserve those metabolic gains while avoiding potential fetal exposure concerns.
Conversely, remaining untreated for obesity during pregnancy carries documented risks: gestational diabetes rates approach 30% in untreated women with obesity, and preeclampsia risk doubles or triples. This is why some maternal-fetal medicine specialists may recommend continuing GLP-1 therapy through early pregnancy in high-risk cases, though this remains a shared decision-making conversation with your clinical team, not a standard protocol.
Personalized Fertility Planning with PlexusDx Genetic Testing
PlexusDx's Precision Peptide Genetic Test identifies variations in genes like GLP1R, FTO, and MC4R that influence how your body responds to weight loss therapy and metabolic hormones. Understanding your genetic predispositions can help you and your doctor estimate how quickly you might achieve weight loss goals before pausing treatment for pregnancy. The test maps 14 metabolic pathways and 49 peptides, offering insight into your individual response profile.
If genetic analysis suggests you'll respond optimally to semaglutide, you can prioritize treatment earlier in your family planning timeline. Conversely, if testing indicates a slower response pattern, your team might recommend starting sooner or choosing alternative approaches. At $99 as an add-on after your first month of PlexusDx treatment, this test provides actionable data for coordinating weight loss and conception goals.
How Your Genetics Influence GLP-1 Response
Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.
Access Personalized GLP-1 Care Through PlexusDx
PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.
Frequently Asked Questions
Do I need to stop semaglutide immediately if I find out I'm pregnant?
Yes. Current medical guidelines recommend discontinuing semaglutide as soon as pregnancy is confirmed, ideally within the first few weeks. Notify your OB/GYN and prescriber right away. Any nausea, vomiting, or abdominal pain during early pregnancy should be evaluated promptly, as these can overlap with semaglutide side effects and pregnancy symptoms.
How long should I wait after stopping semaglutide before trying to conceive?
The medication clears your system within 1–2 weeks after your last dose, so most clinicians recommend waiting at least 2–4 weeks to allow complete clearance and for any residual side effects to resolve. Your doctor may recommend a longer interval based on your individual health profile. Starting prenatal vitamins (including folic acid) immediately after stopping is standard practice.
Can I restart semaglutide after pregnancy and breastfeeding?
Yes, semaglutide is not recommended during breastfeeding due to limited safety data, but you can restart it after weaning. Many women successfully resume PlexusDx semaglutide therapy postpartum to manage weight regain and improve long-term metabolic health. Your prescriber will reassess your health status and may adjust your starting dose.
What if I become pregnant accidentally while on semaglutide?
Stop the medication immediately and contact your OB/GYN. Accidentally taking semaglutide in early pregnancy is not known to cause specific birth defects based on limited case reports, but your doctor will want to monitor you closely. Genetic counseling or specialized ultrasound may be offered depending on how early the exposure occurred.
Does PlexusDx support pregnancy planning while on treatment?
Absolutely. PlexusDx recommends discussing family planning with your prescriber at your initial consultation so your treatment plan aligns with your conception timeline. Your prescription can be adjusted or paused as you approach pregnancy. The PlexusDx Precision Peptide Genetic Test ($99) can help estimate your likely weight loss timeline to better coordinate your goals.
Are there safer weight loss options if I'm actively trying to conceive right now?
If you're currently attempting pregnancy, discuss non-pharmacologic approaches (diet, exercise, sleep, stress management) with your doctor first. If medication is needed, some alternatives have longer pregnancy safety records, though none are ideal during active conception attempts. PlexusDx can help you plan a timeline to start semaglutide now and pause before conception attempts, rather than delaying treatment entirely.
Related Reading
Pricing and availability current as of July 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.
Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.
Medical and Editorial Standards
Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.
Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.
Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.
Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.
Share:
Navigating Ozempic Dosing: What’s the Highest Dose and Your Personalized Path with TrimRx
Safe Injection Practices: Can I Reuse My Ozempic Pen Needle?